Adjuvant Treatment of Early Non–Small Cell Lung Cancer in the Era of Immunotherapy

Adjuvant Treatment of Early Non–Small Cell Lung Cancer in the Era of Immunotherapy

Adjuvant Treatment of Early Non–Small Cell Lung Cancer in the Era of Immunotherapy

What role might immunotherapy play in the adjuvant treatment of early-stage non-small cell lung cancer? Explore the latest clinical trial data.

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Standard of care treatment for resectable early-stage NSCLC usually includes surgery in combination with neoadjuvant or adjuvant platinum-based chemotherapy; however, metastatic disease often develops. To lower the risk for recurrence, an area of active research is the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for early-stage NSCLC. Several immune checkpoint inhibitors are now being investigated in early-stage NSCLC, with promising results reported, suggesting a role for the use of neoadjuvant and adjuvant therapy with immune checkpoint inhibitors in early-stage NSCLC.

    This educational activity will review the role of immunotherapy in early-stage NSCLC as adjuvant treatment, recent clinical data and the latest advances for immune checkpoint inhibitors as adjuvant treatment, and recent and ongoing clinical trials for adjuvant and neoadjuvant immunotherapy for the treatment of early-stage NSCLC so that clinicians are better able to integrate emerging data and new treatment options into clinical practice and inform, educate, and refer patients to clinical trials when appropriate.

  • Disclosure of Conflicts of Interest

    Disclosure of Conflicts of Interest
    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: Heather Wakelee, MD, FASCO, reported a financial interest/relationship or affiliation in the form of Consulting: Mirati Therapeutics, AstraZeneca Pharmaceuticals LP (ended), and Blueprint Medicines (ended). Contracted research: ACEA Biosciences (ended); Arrys Therapeutics (ended); AstraZeneca/Medimmune; Bristol-Myers Squibb Co; Celgene Corp (ended); Clovis Oncology (ended); Genentech/Roche; Helsinn Therapeutics (US) Inc; Merck & Co, Inc; Novartis Pharmaceuticals Corp; Seagen; and Xcovery.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C and Adrienne N. Nedved, MPA, PharmD, BCOP; hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This educational activity is designed for thoracic surgeons, thoracic oncologists, medical oncologists, pathologists, advanced practice providers (physician assistants/nurse practitioners, pharmacists), oncology nurses, and other healthcare professionals involved in the team-based care of patients with early NSCLC.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Evaluate the role of immunotherapy in early-stage NSCLC as adjuvant treatment
    • Assess recent clinical data on immune checkpoint inhibitors as adjuvant treatment for patients with early-stage NSCLC, and how they may fit into current treatment strategies
    • Review ongoing phase 3 clinical trials evaluating adjuvant immunotherapy for the treatment of early-stage NSCLC
  • Accreditation and Credit Designation Statements

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits.  Approval is valid until 03/30/2023 PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education JA4008106-0000-22-005-H01-P. 

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Commercial Support

    This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free